Yap, Kevin Yi-Lwern, Chui, Wai Keung and Chan, Alexandre. (2011) Development of a chemotherapy regimen interaction database for the mobile internet : detecting interactions with psychotropics through OncoRx-MI. Informatics for Health and Social Care, Vol.36 (No.3). pp. 132-146. ISSN 1753-8157

Preview	PDF (Article) WRAP_WarwickU-Manuscript_OncoRx-MI_YapK.pdf - Submitted Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (202Kb)
Preview	PDF (Figures) WRAP_WarwickU-Figures_OncoRx-MI_YapK.pdf - Supplemental Material - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (600Kb)

Abstract

Introduction. Cancer patients are at high risk of drug-drug interactions (DDIs). Clinicians need to know the magnitude of DDIs so as to better manage their patients' drug therapies. We have previously created a novel interaction database for oncology prescriptions (OncoRx). In this project, we leverage on 3G networks to further develop this database into an iPhone-specific application for the mobile internet (OncoRx-MI). Methodology. Data on anticancer drugs (ACDs), chemotherapy regimens (CRegs) and DDIs with psychotropics were compiled from various hardcopy and online resources, and published articles from PubMed, Scopus and Science Direct. The database and iPhone web documents were designed using Adobe Dreamweaver CS4 and associated with a combination of open-source programming scripts. Results. OncoRx-MI currently detects over 5000 DDIs (69.3% pharmacokinetic, 30.7% pharmacodynamic) between 256 single-agent and combination CRegs with 51 psychotropic drugs. OncoRx-MI fits the iPhone screen configuration, and displays information regarding the regimen, pharmacokinetics of the drugs and detected DDIs in tabular format for improved usability. Conclusion. OncoRx-MI is the first mobile DDI application of its kind which detects interactions for combination CRegs. Future versions will include DDIs with other drug categories. Usability studies on its impact in clinical practice will also be carried out.

Item Type:	Journal Article
Subjects:	Q Science > QA Mathematics R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Science > WMG (Formerly the Warwick Manufacturing Group)
Library of Congress Subject Headings (LCSH):	iPhone (Smartphone) -- Computer programs, Drug interactions -- Computer programs, Antineoplastic agents -- Computer programs, Chemotherapy -- Computer programs, Psychotropic drugs -- Computer programs
Journal or Publication Title:	Informatics for Health and Social Care
Publisher:	Informa Healthcare
ISSN:	1753-8157
Date:	September 2011
Volume:	Vol.36
Number:	No.3
Number of Pages:	15
Page Range:	pp. 132-146
Identification Number:	10.3109/17538157.2011.584996
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	National University of Singapore
References:	1. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167-181. 2. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008;75:1-12. 3. Matta A, Ralhan R. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol 2009;1:6. 4. Lordick F, Jäger D. Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. Gastrointest Cancer Res 2008;2:187-197. 5. Herbst RS, Lynch TJ, Sandler AB. Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clin Lung Cancer 2009;10:20-27. 6. Yap KY-L, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008;30:1385-1407. 7. Karas Jr. S. The potential for drug interactions. Ann Emerg Med 1981;10:627-630. 8. Buclin T, Mazzocato C, Berney A, Stiefel F. Psychopharmacology in supportive care of cancer: a review for the clinician. IV. Other psychotropic agents. Support Care Cancer 2001;9:213-222. 9. Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest 2006;24:704-712. 10. China Internet Network Information Center. Statistical survey report on the internet development in China [Internet]. China; 2008 - [cited 2009 March 20]; Available from: http://www.cnnic.cn/uploadfiles/pdf/2008/2/29/104126.pdf 11. Yap KY-L, Chen YZ, Chui WK, Chan A. Oncoinformatics for the healthcare professional: oncology databases and blogs. Internet Journal of Oncology 2009;6:1-22. 12. American Society of Health-System Pharmacists. AHFS Drug Information website [Internet]. Bethesda, MD; 2008 - [cited 2009 May 27]; Available from: http://www.ahfsdruginformation.com 13. British Medical Association, Royal Pharmaceutical Society of Great Britain. Digital British National Formulary [Internet]. London: BMJ Publishing Group Ltd., RPS Publishing,; 2007 - [cited 2009 May 27]; Available from: http://www.bnf.org 14. Lexi-Comp. Inc. Lexi-Comp® ONLINE™ [Internet]. Hudson, Ohio; 2007 - [cited 2009 May 27]; Available from: http://www.lexi.com 15. Thomson Healthcare. Micromedex® Healthcare Series [Internet Database]. 2007 - [cited 2009 August 8]. Available from: http://www.micromedex.com 16. Polen HH, Zapantis A, Clauson KA, Jebrock J, Paris M. Ability of online drug databases to assist in clinical decision-making with infectious disease therapies. BMC Infect Dis 2008;8:153. 17. Clauson KA, Polen HH, Peak AS, Marsh WA, DiScala SL. Clinical decision support tools: personal digital assistant versus online dietary supplement databases. Ann Pharmacother 2008;42:1592-1599. 18. Clauson KA, Polen HH, Marsh WA. Clinical decision support tools: performance of personal digital assistant versus online drug information databases. Pharmacotherapy 2007;27:1651-1658. 19. Wikipedia. 3G (3rd Generation) [Internet]. 2009 - [cited 2009 November 8]; Available from: http://en.wikipedia.org/wiki/3G 20. Zabrek EM. Advance to the 21st Century with the iPhone 3G [Internet]. Fairfield, Iowa: Thaddeus Computing, Inc.; 2008 - [cited 2009 November 8]; Available from: http://www.iphonelife.com/issues/oct08/MobileMedical 21. Yap KY-L, Kuo EY, Lee JJJ, Chui WK, Chan A. An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. Support Care Cancer 2009;September 9:(epub ahead of print). 22. Yap KY, Chan A, Chui WK, Chen YZ. Cancer informatics for the clinician: an interaction database for chemotherapy regimens and antiepileptic drugs. Seizure 2010;19:59-67. 23. Solimando DAJ. Drug Information Handbook for Oncology. 6th ed. Hudson, Ohio: Lexi-comp; 2007. 24. American Society of Health-System Pharmacists. AHFS Drug Information. 2007 ed. Bethesda, MD: American Society of Health-System Pharmacists Inc.; 2007. 25. British Medical Association, Pharmaceutical Society of Great Britain. British National Formulary. 53rd ed. London, UK: BMJ Publishing Group Ltd & RPS Publishing; 2007. 26. Tatro DS. Drug Interaction Facts: The Authority on Drug Interactions. 2008 ed. St. Louis, MO: Facts & Comparisons; 2008. 27. Hansten PD, Horn JR. Hansten and Horn's Drug Interactions Analysis and Management. 3rd ed. Vancouver, Washington: Lippincott Williams & Wilkins; 2008. 28. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook with International Trade Names Index. 15th ed. Hudson, OH: Lexi-comp Inc.; 2007-2008. 29. Thomson Healthcare. Micromedex® Healthcare Series (version 5.1) [Intranet Database]. 2007 - [cited 2009 August 8]. Available from: http://www.thomsonhc.com/hcs/librarian/PFPUI/fV1mNyY303TXxR 30. BC Cancer Agency. BCCA cancer drug manual [Internet]. 2007 - [cited 2009 August 8]; Available from: http://www.bccancer.bc.ca/HPI/DrugDatabase/default.htm 31. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34:D668-D672. 32. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL, Shafa F, Stuart JM, Altman RB. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenomics J 2001;1:167-170. 33. UpToDate Inc. UpToDate Online 16.2 [Intranet Database]. UpToDate Inc. 2008 - [cited 2009 April 13]. Available from: http://www.uptodateonline.com 34. WebMD Inc. Medscape® drug interaction checker [Internet]. New York, NY [cited 2008 January 21]; Available from: http://www.medscape.com/druginfo/druginterchecker 35. Drugsite Trust. Drugs.comTM: drug interactions checker [Internet]. Auckland; 2000 - [cited 2008 October 31]; Available from: http://www.drugs.com/drug_interactions.html 36. Discovery Communications LLC. Discovery Health Drug Interaction Checker [Internet]. 2007 - [cited 2008 March 18]; Available from: http://health.discovery.com/webapps/drugchecker.do?jspLetter=A 37. Healthwise Incorporated. AOL Health Drug Interaction Checker [Internet]. 2006 - [cited 2008 March 18]; Available from: http://drugchecker.aol.com/hwrxic/home/index.aspx 38. Gold Standard Inc. Caremark Drug Interactions [Internet]. [cited 2009 August 8]; Available from: http://cpref.gsm.com/inter.asp?r=8084 39. Enhanced Medical Decisions Inc. DoublecheckMD.comTM [Internet]. 2007 - [cited 2009 August 8]; Available from: http://www.doublecheckmd.com 40. Express Scripts Inc. Drug Digest interactions checker [Internet]. 2007 - [cited 2008 January 21]; Available from: http://www.drugdigest.org/DD/Interaction/ChooseDrugs 41. Thomson Reuters. Physicians' Desktop Reference (PDRhealthTM) Drug Interaction Tool [Internet]. 1984 - [cited 2008 March 18]; Available from: http://pdrhealth.com/health/health-tools-drug-interactions.aspx 42. New Dream Network LLC. DreamHostTM web hosting [Internet]. Brea, CA; 1996 - [cited 2009 May 27]; Available from: http://www.dreamhost.com 43. French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000;18:3115-3124. 44. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998;16:2651-2658. 45. Tesch H, Diehl V, Lathan B, Hasenclever D, Sieber M, Ruffer U, Engert A, Franklin J, Pfreundschuh M, Schalk KP, Schwieder G, Wulf G, Dolken G, Worst P, Koch P, Schmitz N, Bruntsch U, Tirier C, Muller U, Loeffler M. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 1998;92:4560-4567. 46. Yap KY-L, Chuang X, Lee AJM, Lee RZ, Lim L, Lim JJ, Nimesha R. Pharmaco-cybernetics as an interactive component of pharma-culture: empowering drug knowledge through user-, experience- and activity-centered designs. Int J Comput Sci Issues 2009;3:1-13. 47. Tan EL, Stark H, Lowinger JS, Ringland C, Ward R, Pearson SA. Information sources used by New South Wales cancer clinicians: a qualitative study. Intern Med J 2006;36:711-717. 48. Yap KY-L, Chan A, Chui WK. Opinions on drug interaction sources in anticancer treatments and parameters for an oncology-specific database by pharmacy practitioners in Asia. Health Services Insights 2010;3:1-12.
URI:	http://wrap.warwick.ac.uk/id/eprint/38528

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item